gemfibrozil d6

AH057 is a novel JAK inhibitor, effectively blocking the JAK/STAT pathways by directly inhibiting JAK1/2 kinase activities, and leading to compromised cell proliferation and invasion, increasing apoptosis, arrested cell cycles, and impairing tumor progression in vitro and in vivo

Gemfibrozil-D6 is intended for use as an internal standard for the quantification of gemfibrozil by GC- or LC-MS. Gemfibrozil (T1415) is a peroxisome proliferator-activated reporter α and PPARγ agonist. In vivo, gemfibrozil reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia. Gemfibrozil (T1415) reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C) motif ligand 2 (CCL2) in ApoE-/- mice. Formulations containing gemfibrozil have been used in the treatment of high cholesterol.

Gemfibrozil-D6 (Standard) is a reference standard of Gemfibrozil-D6 intended for quantitative analysis, quality control, and related biochemical research applications. Gemfibrozil-d6 is used as an internal standard when quantitatively analyzing Gemfibrozil by gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry. Gemfibrozil is a peroxidase activator α and peroxidase activation receptor γ agonist.